GlassScriptPhysician profile
Luis Fuentes
NPI 1487030417
$1,131.33
in general payments reported to CMS, 2019-2025
15 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $229 · 2021: $35.67 · 2024: $124 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.38 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $338.53 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $191.65 | 2019 | |
| Novo Nordisk INC | $133.39 | 2024-2025 | Ozempic |
| Corcept Therapeutics | $110.07 | 2019 | |
| Lilly USA, LLC | $84.80 | 2020-2025 | Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $40.86 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.94 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.57 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.58 | 2020 | |
| Amgen INC. | $27.85 | 2019 | |
| Pfizer INC. | $26.70 | 2019 | |
| Phathom Pharmaceuticals, INC. | $25.63 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $14.33 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.31 | 2019 | |
| Shire North American Group INC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Fuentes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.